AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deAUG 132 min read$LIMN

Liminatus Pharma Inc.: Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

Liminatus Pharma (Nasdaq: LIMN) said its shares transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective Aug. 4, 2026, keeping the ticker LIMN. Nasdaq’s Hearings Panel granted an extension to regain compliance with the minimum bid price rule, with a deadline of Sept. 3, 2026.

Original reporting
finanznachrichten.de
Published Aug 13, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 11:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$LIMN
Neutral
medium confidence
Mentioned
$LIMN
Relevance
6/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$LIMNNeutralMed
01

Why it matters

The key tradable element is the updated compliance timeline. The transfer keeps the stock trading on Nasdaq under the same ticker (LIMN), but the company must demonstrate compliance by Sept. 3, 2026 to avoid further listing consequences.

02

Market read

This is a concrete exchange-listing risk update with a specific new deadline, which can change the stock’s delisting-risk premium and near-term trading behavior.

03

What to watch

Bid-price compliance can be influenced by financing, reverse splits, or sustained trading-volume improvements, none of which are detailed here.

Relevance 6/10Novelty 6/10Timing: effective Aug. 4, 2026 transfer; compliance deadline Sept. 3, 2026

Background

Liminatus Pharma was moved from Nasdaq Global Market to Nasdaq Capital Market due to minimum bid price noncompliance, and the Nasdaq Hearings Panel granted additional time to fix it.

Company-level read

Ticker impact

$LIMNNeutralMedium confidence
Context

Liminatus transferred from Nasdaq Global Market to Nasdaq Capital Market and received an extension until Sept. 3, 2026 to regain bid-price compliance.

Expected impact

Likely supports downside risk in the near term versus an immediate delisting scenario, but may cap upside until the company demonstrates bid-price compliance by Sept. 3, 2026.

Evidence & confidence

The article is a primary listing-compliance update with a specific new compliance deadline, which typically affects risk premium and liquidity expectations more than fundamentals.

Market effects

Sector

For small-cap biopharma, Nasdaq compliance actions can signal ongoing liquidity/financing risk, influencing sector risk appetite for similar issuers.

Regional

Primarily US microcap listing and liquidity dynamics; limited direct regional spillover.

Global

Low global relevance; mainly affects US trading venues and delisting-risk pricing.

Counterpoint

What could challenge this read

The extension may be viewed as a temporary reprieve, not a resolution, so traders may still fade rallies until bid-price compliance is actually achieved.

Key entities

  • company
    Liminatus Pharma, Inc.

    Nasdaq-listed biopharmaceutical company developing cancer therapies; subject of the listing-compliance update.

  • regulator
    Nasdaq Hearings Panel

    Granted the company an extension to demonstrate minimum bid price compliance.

Read at source← All news

Related articles

AUG 24
$LIMNMed

Liminatus Partners with Korean Firm for CAR

Liminatus Pharma partners with Synex Consulting to advance its CAR-T cell therapy in South Korea. The Ministry of Food and Drug Safety authorized a Phase 1/2a clinical study. Liminatus went public via a SPAC last year. Shares are down 8.2% to $4.73, with a $6.4M market cap.

ocbj.com2 min
JUL 6
$LIMNMed

Liminatus Pharma, Inc. (LIMN): Completion of Acquisition or Disposition of Assets

Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 tm2619730d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AMENDED AND RESTATED MERGER AGREEMENT dated June 29, 2026 by and among InnocsAI LLC, Delaware limited liability company (the “ Company ”), NamChul Jung, as the Members’ Representative (the “ NamChul Jung ”), and Liminatus Pha

SEC EDGAR 8-K3 min
JUL 1
$LIMNMedAI 8/10

Liminatus Pharma Amends Merger Agreement With InnocsAI To Expand Oncology Pipeline

Liminatus Pharma (LIMN) amended its merger agreement with InnocsAI LLC to expand its oncology pipeline. The deal is now expected to close July 2, 2026, before stockholder approval. InnocsAI holders will receive Liminatus common stock and newly designated non-voting convertible preferred issued at $0.20/share, implying ~$320M value, plus CVRs on 20% of future net proceeds.

rttnews.com4 min
SEP 17
$PHOSMed

First Phosphate shareholders could see reduced dilution risk, Noble says after SERV news

First Phosphate Corp. (PHOS) may face reduced equity dilution after Noble Capital Markets noted potential lower funding needs for its Bégin-Lamarche project, supported by Swiss Export Risk Insurance (SERV) and other financing. SERV could provide up to US$212.5 million, reducing the equity requirement to about US$82.5 million. Noble maintains an Outperform rating and $25.50 price target.

proactiveinvestors.com2 min
SEP 17
$AONHighAI 9/10

Aon raises $13.75 billion to support USI acquisition

Aon raised $13.75 billion in senior notes, guaranteed by its subsidiaries, with maturities from 2029 to 2056 and coupons ranging from 5.350% to 6.450%. The funds, approximately $13.4 billion after expenses, will support the USI Advantage Corp. acquisition and general corporate purposes. The notes include redemption protections tied to the deal's completion.

tipranks.com2 min